CXCR2 and neoplasm: Research indicates that the mechanism of action of this inhibitor may involve reducing tumor accumulation of CXCR2+ MDSCs in mice, enhancing the efficacy of T cell immunotherapy[108], or increasing the tumor accumulation and activation status of KIL cells (a cultured murine NK cell line) for adoptive transfer by inhibiting PMN-MDSC trafficking[107].